摘要
目的:评价左氧氟沙星与坦索罗辛联合治疗Ⅲa型前列腺炎的有效性及安全性。方法:采用随机、双盲、平行对照临床试验研究方法,通过NIH-CPSI评分、前列腺按摩液(EPS)检查,筛选出240例Ⅲa型前列腺炎患者,随机分为左氧氟沙星组(80例)、联合组(80例)和坦索罗辛组(80例)。所有患者均行入组前、治疗后第8周随访并进行NIH-CPSI评分、EPS WBC计数及药物不良反应的评估。结果:左氧氟沙星联合坦索罗辛治疗Ⅲa型前列腺炎的有效率为83.8%,优于其他两单剂治疗组(P<0.05),该组疼痛或不适症状评分、排尿症状评分、生活质量评分和NIH-CPSI总分比治疗前有显著降低(P<0.01),疗效亦优于其他单剂治疗的2组(P<0.05);联合组治疗前后的WBC计数非常显著性差异(P<0.01),单剂组治疗前后EPS中WBC计数差异有显著性(P<0.05);3组不良反应发生率和对药物的耐受性均无显著性差异(P>0.05),无严重不良反应事件发生。结论:左氧氟沙星联合坦索罗辛能更有效地缓解Ⅲa型前列腺炎患者的疼痛不适和排尿等症状,改善患者的生活质量,且耐受性较好,治疗Ⅲa型前列腺炎安全有效。
OBJECTIVE To evaluate the efficacy and safety of combined administration of levofloxacin and tamsulosin in the treatment of type Ⅲa prostatitis.METHODS 240 patients diagnosed as type Ⅲa prostatitis were randomly divided into 3 groups.Patients in these groups were given levofloxacin 500 mg,levofloxacin 500 mg combined with tamsulonsin 0.2 mg,tamsulonsin 0.2 mg respectively.Clinical results were observed and NIH-CPSI scores were measured before and after 8-week treatment.RESULTS The total effective rates of 3 groups were 63.8%,83.8%,52.5%,respectively;and there was significant difference compared with 2 mono-drug therapy groups（P〈0.05）.Clinical symptoms such as scores of pain、urination、quality of life and total NIH-CPSI were improved respectively.Especially the scores of combination group was significantly improved compared with other two groups（P〈0.01）.The counts of WBCs in EPS between pre-and post treatment showed high significant difference in combination group（P〈0.01）,meanwhile statistically significance（P〈0.05） in other two groups were observed.There was no significant difference（P〉0.05） among all 3 groups in adverse drug reactions.CONCLUSION Oral levofloxacin 500 mg once daily combined with tamsulosin is a rational and safety dosage regimen in the treatment of type Ⅲa prostatitis.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2012年第15期1212-1214,共3页
Chinese Journal of Hospital Pharmacy
